Intellia Therapeutics has secured FDA priority review for its hereditary angioedema gene editing therapy lonvo z and reported fresh positive trial data, while also advancing phase 3 programs in ATTR ...
Source LinkIntellia Therapeutics has secured FDA priority review for its hereditary angioedema gene editing therapy lonvo z and reported fresh positive trial data, while also advancing phase 3 programs in ATTR ...
Source Link
Comments